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Summary 
Stimulation of the Fas (APO-1, CD95) receptor, which is present on a variety of cells, usually 
triggers a process of programmed cell death.  Systemic injection of anti-Fas antibody into mice 
leads to fulminant liver destruction resulting from massive hepatocyte apoptosis, and to rapid 
death. Hepatocytes bear Fas but do not express Bcl-2, a protein that plays, in a number of con- 
ditions, a protective role against apoptosis. We have generated mice whose liver expresses Bcl-2 
as the result of a bcl-2 transgene placed under the control of the hepatocyte-specific otl-anti- 
trypsin gene promoter, but is otherwise not distinguishable from that of normal mice. These 
mice display a marked to almost total resistance to liver damage induced by anti-Fas antibody 
injection. This protective effect of Bcl-2 occurs in the absence of significant variations, in the 
stimulated livers, in the level of expression of other proteins also involved in resistance or sensi- 
tivity to apoptosis, namely Bcl-x, Bax, Bad, Bak, and p53. Mice with protected livers, how- 
ever, die almost as rapidly as normal mice, which indicates that acute lethality results from stim- 
ulation of Fas receptors present on other target organs or cells. 
T 
he Fas  receptor (APO-1,  CD95)  is a membrane pro- 
tein of the tumor necrosis factor-nerve growth factor 
receptor family, which,  upon  interaction  with  its  ligand, 
Fas-L,  another membrane protein,  or upon  triggering by 
anti-Fas antibodies,  usually acts as an inducer of apoptosis 
(1,  2). This results from an incompletely understood chain 
of events that culminates in intracellular proteolysis involv- 
ing the IL-1 converting enzyme (ICE) 1 and other proteases 
of similar specificity (3, 4). In a number of apoptotic condi- 
tions, expression or overexpression of the protein Bcl2 in- 
duces,  in  a  variety  of cells,  some  degree  of protection 
against cell  death.  This has also been observed in vivo in 
transgenic mice overexpressing Bcl-2 in cells of the T  or B 
lymphocytic lineages or in neurons  (5-7).  However, con- 
flicting results have been published concerning the capacity 
of cells transfected with bcl-2 cDNA to resist Fas-mediated 
apoptosis (8-11). 
Injection of anti-Fas antibodies into mice leads to a very 
rapid and massive destruction  of hepatocytes and to death 
within a few hours (12).  This results from the triggering of 
the  Fas receptor present on the hepatocytes and not from 
another effect of the antigen-antibody reaction, since MRL 
1Abbreviations used in this paper: ICE, IL-l-converting enzyme; PGK-1, 
phosphoglycerate kinase 1. 
mice homozygous for the lpffg mutation are entirely resis- 
tant to anti-Fas injection; this mutation alters the intracyto- 
plasmic domain of the Fas molecule, resulting in a lack of 
function  (1).  Since activated T  lymphocytes express Fas-L 
on  their  membranes  (13,  14),  the  high  vulnerability  of 
hepatocytes to stimulation of their Fas receptors may play 
an important role in liver damage of severe forms of im- 
mune-mediated  hepatitis.  In  this  report,  we  show  that 
transgenic  mice expressing Bcl-2  in  their hepatocytes are 
protected against fulminant liver destruction resulting from 
anti-Fas antibody injection. 
Materials and Methods 
Construction of the  Transgene and  Generation of Transgenic Mice. 
A  2.9-kb  DNA fragment containing  an internal  poliovirus  se- 
quence  (ribosome  landing  pad) followed by a CAT gene  and a 
SV40 poly (A) sequence  was purified  after PstI digestion  of the 
plasmid pSVGHpolioCAT (15) and inserted into the PstI site of a 
pBluescript KS plasmid (Stratagene Inc., La Jolla, CA) to generate 
pRCAT. The pAATRCAT plasmid was generated  by inserting 
the  human  otl-antitrypsin  gene  promoter  (16), digested  with 
Xbal and SacI into pRCAT previously  digested with the same 
enzymes. The human bcl2 cDNA was obtained by digesting the 
phosphoglycerate  kinase  (PGK)-bcl-2 plasmid  (7)  with  EcoRI 
and  the  resulting  0.9-kb fragment was,  after blunting,  inserted 
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pAATbcl2RCAT. The transgene  used for oocyte injections  was 
excised  by digesting  pAATbcl2R.CAT with BssHII, isolated  on 
agarose  gel  and  purified  on  NACS  columns  (GIBCO  BRL, 
Gaithersburg,  MD). Use ofa transgene expressing a polycystronic 
mlLNA with  a reporter CAT sequence was intended as an at- 
tempt to follow more easily the expression  level of the transgene 
with a CAT assay, but this approach was found less sensitive and 
not useful. Transgenic mice were generated as described (17) us- 
ing (C57Bl/6￿  1 eggs. Founder transgenic  mice, identi- 
fied by Southern blotting, were then mated with C57BL/6 mice. 
Three transgenic  lines were obtained, with respectively  2, >10, 
and  >30  copies  of the  transgene;  only the  second hne,  which 
corresponded to the highest expressor  line as judged by Western 
blotting of liver extracts,  was used for further experiments.  Pro- 
duction of PGK-bcl2 transgenic  mice has already been described 
(7);  these  last mice  had  also  been  bred  on  a  C57BL/6  back- 
ground. Mouse colonies were expanded by mating founder ani- 
mals with C57BL/6 mice. All mice were purchased from IFFA 
CREDO (Lyon, France). 
Anti-Fas Antibody Injections and Histologic Examination.  5--8-wk- 
old  nontransgenic  httermates  or  transgenic  mice  bred  on  a 
C57BL/6 background were injected intravenously with 10 I-tg of 
an affinity-purified  hamster monoclonal antibody against mouse 
Fas antigen(Jo2)  (12) diluted in 100 ~I of  a 0.9-g/liter NaC1 solu- 
tion.  Mice were killed at various times or autopsied immediately 
after death,  and fragments  of tissues were fixed in vivo with 4% 
paraformaldehyde in PBS,  embedded in paraffin,  and 5 ~m sec- 
tions were stained  with 5 I~m hematoxylin and eosin.  For elec- 
tron microscopy, organs were fixed by in vivo perfusion with 2% 
glutaraldehyde,  1% sucrose in PBS. 
Northern and  Western Blot Analysis.  Total liver  mtLNA was 
extracted by using columns (Qiagen GmbH, Hilden,  Germany) 
according to the manufacturer's instructions.  RNAs (10 ~g) were 
fractionated  on 1% agarose--formaldehyde  gel before blotting. Ni- 
trocellulose  blots of total RNA were hybridized with the follow- 
ing  cRNA  probes  corresponding to  the  complete  coding se- 
quences: mouse fas (18), human bak, bcl-x, and bax (kind gifts of 
J.-C. Martinou, Glaxo IMB, Geneva, Switzerland).  For Western 
blotting, proteins were extracted from minced liver fragments  for 
15 rain at 4~  with RIPA buffer (PBS,  1% NP-40, 0.5% sodium 
deoxycholate, and 0.1%  SDS)  containing aprotinin  and PMSF. 
After centrifugation at  15,000 g, protein in the supematants was 
quantitated by the Bradford method and 100 Ixg protein per lane 
was run in 10% polyacrylamide gels. Proteins were transferred  to 
nitrocellulose  membranes,  which  were  then  blocked  with  5% 
nonfat milk in TBS-T (TBS  [20 mM Tris HC1, 500 mM NaC1, 
pH 7.5] and Tween 0.1%), and the washed membranes were in- 
cubated  for  1  h  at  20~  with  one  of the  following:  an  anti- 
human Bcl-2  mouse  monoclonal antibody  (BCL2  100,  kindly 
provided by D.Y. Mason, John Radcliffe Hospital,  Oxford, UK) 
at a 1 : 200 dilution, a hamster anti-mouse BcI2 monoclonal anti- 
body (3Fll; PharMingen, San Diego, CA) at a 1:1,000 dilution, 
a mouse anti-p53 monoclonal antibody (DO1; Santa  Cruz Bio- 
technology Inc., Santa Cruz, CA) at a 100 ng/ml concentration, 
a rabbit  anti-mouse Bax  (1696-4)  (19),  Bcl-x  (1695-5)  (20),  a 
Bad (C-20; Santa Cruz Biotechnology Inc.), or a hamster anti-Fas 
antibody (Jo2) (12), all used at a concentration between 200 and 
500 ng/ml). Rabbit anti-mouse ICE antibodies  (R10311; a kind 
gift of D.G. Miller,  Merck Research Laboratories,  Rahway, NJ) 
were used at a 1:1500 dilution.  Peroxidase-conjugated F(ab)2 goat 
anti-hamster  IgG  (Jackson  lmmunoResearch  Labs.,  Inc.,  West 
Grove, PA), goat anti-mouse IgG, or anti-rabbit IgG (Santa Cruz 
Biotech. Inc.) was used for 1 h as secondary antibody at 400-800 
ng/ml. Membranes were washed with TBS-T, incubated in en- 
hanced chemiluminescent (ECL)  detection reagents  (Amersham 
International, Amersham Bucks, UK) for 1 min at room temper- 
ature,  and exposed to X-Omat film (Eastman Kodak Co., Roch- 
ester, NY). 
Results  and Discussion 
By Western blotting (Fig.  1 a), normal mouse liver was 
found not to contain  detectable  Bcl-2 protein.  To obtain 
mice  with  a  strong  hepatocyte  expression  of Bcl-2,  we 
generated  transgenic  mice  in  which  human  bcl-2  cDNA 
was placed under the control of a cel-antitrypsin promoter, 
which we have found in various transgenic models to be a 
very  effective  hepatocyte-specific  promoter  (16,  21,  and 
Kaya, G. and P. Vassalli,  unpublished observations).  Three 
independent  mouse lines  were  obtained,  and  the line  ex- 
pressing the highest level of Bcl-2 on Western blots ofhver 
extracts  was  selected  (Fig.  1  b);  no  human  Bcl-2  protein 
was detectable in the other organs tested  (Fig.  1 b). Except 
for Bcl-2 expression,  livers from these mice were indistin- 
guishable from those  of normal mice in gross appearance, 
histology, and expression  of various proteins  and mR.NAs 
by Western and Northern blotting (not shown),  including 
the  Fas  protein  (Fig.  1  c).  When  transgenic  and  control 
mice  were  injected  intravenously  with  10  tzg of the Jo2 
monoclonal antibody,  deaths  occurred within a few hours 
in both types of mice, but gross appearance of the liver was 
strikingly different:  massively hemorrhagic,  shrunken,  and 
dittluent  in  normal mice,  and  normal  in  transgenic  mice. 
Pilot experiments showed that histologic lesions in general 
were inconspicuous in normal mice within the first 50-60 
min after antibody injection, but appeared very rapidly af- 
terwards.  On this  basis,  comparison of the livers  of trans- 
genic and normal mice was performed on animals killed at 
various times before death,  and mice examined at the time 
of death. 
Histologic study of the livers of four normal mice killed 
75  rain  after  antibody injection  showed  extensive  lesions 
characterized by massive hepatocyte destruction with cyto- 
plasmic  swelling  of most  surviving  hepatocytes  and  fre- 
quent nuclear chromatin condensation, indicative of apop- 
tosis, and by intraparenchymatous hemorrhages in the areas 
with  the most extensive hepatocyte damage  (Fig.  2,  a and 
c).  The livers of three transgenic  mice killed 30 min later, 
i.e.,  105 rain after injection, showed, in contrast, no or dis- 
crete histologic changes (Fig. 2, b and d), with total preser- 
vation of the tissue architecture,  no hemorrhages,  and oc- 
casional swelling of some hepatocytes. To explore whether 
hepatocyte damage in normal mice is preceded or accom- 
partied by changes in the levels of gene products that have 
been implicated in apoptotic death,  changes that might be 
compensated by the expression of Bcl-2 in transgenic mice, 
Western  and Northern blots were performed on hver ex- 
tracts  taken  at  various  times  after  antibody injection.  No 
significant variations were found in the levels of the Bcl-x 
protein  (Fig.  1 d;  a member of the Bcl-2 family expressed 
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ses. (a) Blots from lysates of  brain 
and liver of a normal mouse, re- 
acted with anti-mouse Bcl2 anti- 
body. No Bcl2 is detected in the 
liver in contrast to the brain. (b) 
Blots from lysates of various or- 
gans  of  AAT-bc12  and  PGK- 
bd2,  or of normal mouse liver, 
reacted  with  anti-human  Bcl2. 
In AAT-bcI2 mice, human Bcl2 
is  present  only  in  the  liver, in 
PGK-bc12,  it  is  present  in  the 
brain and liver (and other organs, 
not  shown), and it is absent in 
normal mouse liver. (c) Blot from 
lysates of liver  of a  AAT-bcl2 
transgenic mouse and its control 
littermate, reacted with  anti-Fas 
antibody. (d-J) Blots from lysates 
of liver  of normal  mice,  unin- 
jected or 80 rain  after antibody 
injection, reacted with anti-Bcl-x, 
Bax, Bad, and p53 antibodies. 
in normal liver, contrarily to Bcl-2),  the Bax and Bad pro- 
teins (Fig.  1, e and f) or the bak mRNA  (not shown), three 
genes whose  increased  expression has been  shown  to pro- 
mote apoptosis  (22-25).  The level of the protein p53,  sur- 
prisingly  high  in  the  liver,  a  nondividing  tissue,  was  also 
unchanged  after anti-Fas injection  (Fig.  I g). 
10  normal  and  six  transgenic  mice  were  then  injected 
with  anti-Fas  antibody  and  examined  at  the  time  of their 
death,  which  occurred  in  all cases,  although  slightly  more 
rapidly with  normal mice  (2.1  +  0.6  compared  to  3.3  +- 
1.2  h  with  transgenic  mice;  Fig.  3).  Massive  hemorrhagic 
destruction  of the  liver was  observed  in  all  control  mice, 
whereas four transgenic  mice showed no or minor hepato- 
cyte  alteration,  consisting  at  most  of some  degree  of cell 
swelling (Fig. 2f).  The two remaining transgenic mice had 
focal areas with  more  distinctive  signs  of cell  damage  and 
some apoptotic nuclei, but the liver structure was preserved 
without hemorrhages. 
These observations raise two questions:  (a) What are the 
mechanisms  and  the  target  tissue(s)  of Fas-induced  death, 
since what appears, in some cases at least, as a complete he- 
patic  protection  affords  no  protection  against  death?  (b) 
What  is  the  mechanism  of the  Bcl-2-induced  hepatocyte 
protection? 
In addition to hepatocytes and lymphoid cells in the thy- 
mus  and  peripheral  lymphoid  organs,  the  Fas  receptor  is 
expressed  in  several  organs,  in  particular  the  heart,  lung, 
kidney, and small intestine  (26, 27). No histologic or ultra- 
structural  (in  the  case  of the  myocardium)  alterations  that 
might explain the  rapid death of animals were  observed in 
these  organs.  To  explore  whether  a  transgenic  expression 
of Bcl-2  expressed in  many tissues besides  the liver might 
afford a better level of protection against the lethal effect of 
anti-Fas antibody injection,  we used mice expressing a hu- 
man bcl-2 transgene placed under the control of the PGK-1 
promoter,  since  the  promoter  of this  ubiquitous  protein 
should  lead to the  expression  of the  transgene  in  a  variety 
of tissues. These PGK-bcl2 transgenic mice have been used, 
for instance,  to detect the effect of the constitutive  expres- 
sion  of Bcl-2  in  the  brain  during  fetal  development  (7). 
Western blot analysis of various organs from these mice in- 
deed  showed  the  presence  of the  human  Bcl-2  protein 
(Fig.  1 b). In the liver, the level of this protein was compa- 
rable  to  that  found  with  the  AAT-bcl-2  transgenic  line 
(Fig.  1).  Two  PGK-bcl2  transgenic  mice  of  the  same 
C57B1/6  genetic background  were  injected  with  antibody 
and died, but only about 9 h  later (Fig. 3). By gross appear- 
ance,  the  livers  were  not  hemorrhagic,  but  by  histology, 
apoptotic  lesions  were  severe  (Fig.  1  e)  with,  however, 
preservation  of a  number  of hepatocyte  trabeculae  and  no 
massive  hemorrhagic  infiltrates.  More  extensive  studies 
were not performed with these mice, which are difficult to 
breed.  This  limited  observation  is nevertheless  compatible 
with the possibility that constitutive  overexpression of Bcl-2 
elsewhere  than  in  the  liver  exerts  some  protective  effect 
against the most immediate  mechanisms  of death  resulting 
from  anti-Fas  antibody  injection.  These  mechanisms  may 
be  related  to  the  impressive  systemic  effects  observed 
within  10  min  after  antibody  injection  (prostration  and 
progressive  deep  hypothermia).  These  effects  represent 
more than the mere consequences  of a widespread antigen- 
antibody  reaction,  since  mice  homozygous  for  the  lprCg 
mutation  are  resistant  to  anti-Fas  antibody  injection,  al- 
though  they  express as much  antigen  on  their  membranes 
(26). The basis for these systemic effects has remained so far 
elusive:  death  by  cardiovascular  or  respiratory  failure  ap- 
1033  Rodriguez et al. Figure 2.  Histology of the livers. (A and C) Liver from an 8-wk-old nontransgenic littermate  75 rain after injection ofanti-Fas antibody. At low mag- 
nification (A, ￿  100),  the architecture  of the fiver parenchyme  is destroyed; the scattered dark areas represent  hemorrhagic  foci. At higher magnification 
(C, ￿  some very swollen hepatocytes are seen, as well as apoptotic  nuclei characterized by peripheral chromatin  condensation  (arrows); there are nu- 
merous red blood cells. (B and D) Liver from an 8-wk-old transgenic AAT-bcI2 mouse 115 rain after injection of anti-Fas antibody.  At ￿  100 (B) and 
￿  (D), liver appears normal and without hemorrhagic  foci. (E) Liver from a transgenic mouse of the PGK-bcl2  line at the time of death (8.5 h after 
antibody injection;  ￿  In the middle of the picture,  hepatocytes appear normal, whereas laterally, most hepatocytes are at different stages ofapoptosis 
(see arrow for an example ofapoptotic nucleus). No significant intraparenchymamus  hemorrhage  is seen. (F) Liver from an 8-wk-old AAT-bcl2 mouse at 
the time of death (2.3 h after anti-Fas antibody  injection;  ￿  Hepatocytes  appear almost normal although  some are swollen; there is some degree of 
intercellular edema, but not hemorrhage. 
pears  to  be  ruled  out by failure  to  detect  significant  alter- 
ations  by  electrocardiographic  monitoring,  determination 
of blood  gases  and  lactate  levels,  and  histologic  and  ultra- 
structural  examinations  of the  heart  and  lung.  Glycemia 
and  blood electrolytes remained within  control values,  ex- 
cept for an increase in blood potassium  level, as previously 
noted  (12).  Histologic study of all tissues known  to express 
Fas (27)  and of the hypothalamic region did not reveal con- 
spicuous  alterations.  Since injection  of limited amounts  of 
anti-Fas  antibody may be considered a  possible  therapeutic 
approach  in  the  case  of well-differentiated,  not  surgically 
removable hepatomas,  it will be  necessary  to  elucidate  the 
mechanisms  of the  rapid  systemic  and  life-threatening  ef- 
fects ofanti-Fas antibody injection. 
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Figure  3.  Times of death after anti-Fas injections. Times of death of 
controls (ctr) and transgenic mice of the AAT-bcl2 and PGK-bcI2 lines, 
respectively, after intravenous injection of 10/xg of anti-Fas antibody. 
Triggering of the Fas receptors expressed on the hepato- 
cytes induces  the apoptotic destruction  of these cells more 
rapidly than  with  any other  cell types studied  so far.  This 
may be related  to:  (a)  the  intensity  of the  signal  received; 
(b)  shortage  of protective  mechanisms;  or  (c)  a  high  basic 
level of effector mechanisms  of cell death in this  cell type. 
The  effects  of Fas  receptor  stimulation  appear  not  to  be 
merely related to the number of receptors involved, but also 
to the amount and variety ofphosphatases constitutively ex- 
pressed by the  cells  (28);  protein  tyrosine phosphorylation 
is a  very rapid  consequence  of Fas triggering  (29).  In this 
regard, the Fas-binding phosphatase FAP-1 is not expressed 
in the liver (30), which is consistent with the extreme sen- 
sitivity of this organ to the effects of anti-Fas antibody. Pos- 
sible  differences  in  protein  phosphorylation  after antibody 
injections  in  normal  and  Bcl-2-protected  livers  have  not 
been explored. As for a possible shortage of apoptotic-pro- 
tective mechanisms  in  normal hepatocytes,  it was striking 
to observe that Bcl-2 expression is not likely to act by corn- 
pensating a decrease in Bclx or an increase in Bax, Bad,  or 
Bak proteins,  since,  in  contrast  to  what  is  observed with 
some  apoptotic-inducing  conditions  with  other  cell  types 
(31-33),  no significant variations of these proteins  or their 
mRNAs were found in Fas-stimulated livers. Thus,  it may 
be that constitutive  expression of Bcl-2 is more protective 
than that of Bclx in hepatocytes. There is indeed evidence 
that expression of Bd-2 and Bclx may not be in all cells or 
conditions  equally protective against apoptosis (34). Use of 
AAT-bclx transgenic mice might offer some information in 
this respect. Finally, it has been shown with other cell types 
that the  effector mechanism  of Fas-mediated  apoptosis in- 
volves  proteolytic  events,  in  particular  activation  of the 
proteolytic  enzyme  ICE  and  possibly  other  cysteine  pro- 
teases  of the  same  family  (3,  4).  Comparable  proteolytic 
events  are  likely  to  occur  in  Fas-stimulated  hepatocytes. 
Since  hepatocytes  contain  high  amounts  of  ICE  (not 
shown), it will be of interest to explore whether a proteolytic 
cascade  involving  ICE  can be  especially easily induced  or 
activated in hepatocytes,  thus  explaining the high sensitiv- 
ity of these  cells  (which  also synthesize high levels of pre- 
cursors of the coagulation proteolytic cascade) to Fas-medi- 
ated apoptosis. 
Fas-mediated liver injury is likely to play a critical role in 
some forms of immune-mediated  hepatitis, since it has be- 
come evident that activated T  lymphocytes have the ability 
to kill Fas-bearing targets through  their membrane expres- 
sion of Fas-L (1). The present observations raise the possi- 
bility  of  new  therapeutic  approaches  in  life-threatening 
forms of these diseases, by the use ofgene targeting of Bcl-2 
into hepatocytes in vivo or into liver transplants in vitro, or 
by the temporary perfusion of specific antiproteolytic  pep- 
tides that can penetrate within cells. 
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